| Revision as of 03:41, 1 June 2013 editDclutz (talk | contribs)11 editsNo edit summary← Previous edit | Revision as of 03:41, 1 June 2013 edit undoDclutz (talk | contribs)11 editsNo edit summaryNext edit → | ||
| Line 11: | Line 11: | ||
| }} | }} | ||
| '''Anthera Pharmaceuticals, Inc.''' is a biopharmaceutical company focused on developing and commercializing products to treat autoimmune diseases. Anthera's Phase 3 development product candidate, blisibimod, targets elevated levels of B-cell activating factor, or BAFF, which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus, or lupus, Immunoglobin A nephropathy, lupus nephritis, vasculitis, rheumatoid arthritis, idiopathic thrombocytopenia purpura, and others.<ref name=10k>{{cite web|url=http://quote.morningstar.com/stock-filing/Annual-Report/2012/12/31/t.aspx?t=XNAS:ANTH&ft=10-K&d=740adeb41b03cbaebf84e0e2480a09c7 |title=Form 10-K, Anthera Pharmaceuticals, Inc.|date=March 26, |
'''Anthera Pharmaceuticals, Inc.''' is a biopharmaceutical company focused on developing and commercializing products to treat autoimmune diseases. Anthera's Phase 3 development product candidate, blisibimod, targets elevated levels of B-cell activating factor, or BAFF, which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus, or lupus, Immunoglobin A nephropathy, lupus nephritis, vasculitis, rheumatoid arthritis, idiopathic thrombocytopenia purpura, and others.<ref name=10k>{{cite web|url=http://quote.morningstar.com/stock-filing/Annual-Report/2012/12/31/t.aspx?t=XNAS:ANTH&ft=10-K&d=740adeb41b03cbaebf84e0e2480a09c7 |title=Form 10-K, Anthera Pharmaceuticals, Inc.|date=March 26, 2013|publisher=U.S. Securities and Exchange Commission}}</ref> | ||
| ==Product Candidates== | ==Product Candidates== | ||
Revision as of 03:41, 1 June 2013
 | |
| Company type | Public |
|---|---|
| Traded as | Nasdaq: ANTH |
| Industry | Pharmaceuticals |
| Founded | 2004 |
| Headquarters | Hayward, California, U.S. |
| Key people | Paul F. Truex (President and CEO) |
| Website | Anthera.com |
Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products to treat autoimmune diseases. Anthera's Phase 3 development product candidate, blisibimod, targets elevated levels of B-cell activating factor, or BAFF, which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus, or lupus, Immunoglobin A nephropathy, lupus nephritis, vasculitis, rheumatoid arthritis, idiopathic thrombocytopenia purpura, and others.
Product Candidates
- Blisibimod, an investigational anti-BAFF molecule in Phase III trails for the treatment of systemic lupus erythematosus and Phase II trials for the treatment of IgA nephropathy.
References
- "Form 10-K, Anthera Pharmaceuticals, Inc". U.S. Securities and Exchange Commission. March 26, 2013.
